Serious adverse events occurred in eight individuals during the study treatment period or the following 30 days . One event was regarded by the investigator to become possibly linked to a study drug. Adverse events that occurred during treatment in a lot more than 20 percent of patients in any group are shown in Table 2. The most common adverse events were fatigue, headaches, nausea, and insomnia. The nature and frequency of adverse occasions were comparable across treatment groups. Adverse events that happened during treatment in more than 5 percent of patients in virtually any subgroup are listed in the Table S12 in the Supplementary Appendix.New Therapeutic with Promise for Neuroprotection and Treatment in Neonatal Care A University of Minnesota research group headed by James Cloyd, PharmD, Professor of Experimental & Clinical Pharmacology, Lawrence C. Weaver Endowed Chair-Orphan Drug Development, and Director, Center for Orphan Drug Study, received funding to support the study of an intravenous formulation of the anticonvulsant Topiramate , a drug which has demonstrated important neuroprotective properties in preclinical models. Topiramate, in its oral formulation, is currently prescribed to treat epilepsy in kids and adults. In this program, experts are pursuing the long-term goal of creating a novel, FDA-approved, intravenous topiramate for the treatment and neuroprotection of seizures in neonates with hypoxic brain injuries.